ASH 2014 - CLL

Safety Overview of the CLLM1 Trial: Lenalidomide Maintenance Therapy After Frontline Chemoimmunotherapy in High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Functional Evidence that Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The Combination of Alemtuzumab and Ofatumumab in Previously Untreated CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ublituximab plus TGR-1202 in Heavily Pretreated and High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib in Relapsed/Refractory CLL After Allogeneic Stem-Cell Transplant

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Dinaciclib plus Ofatumumab in Patients with Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Ofatumumab in Patients with Relapsed/Refractory CLL in the RESONATE Study

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The RESONATE-17 Trial: Efficacy and Safety of Ibrutinib in Patients with Relapsed/Refractory CLL and del17p

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Page 1 of 3

1
2
3